Some Sort Of Untold Plot On ABT-199 You'll Want To See Or Be Left Out

Patients were randomly assigned to receive certoparin or placebo for six?months, and underwent ultrasonography for DVT every four?weeks. There were significantly less VTE events in the certoparin group compared to placebo (4��3% vs. 8��3%, P?=?0��07) and there was no significant difference in the rate of major bleeding complications (RR 1��67, 95% CI 0��61�C4��52, P?=?0��32). PROTECHT is a randomised, placebo-controlled, double-blind, multicentre study in which outpatients receiving chemotherapy for metastatic or locally advanced solid tumours were randomised in a 2:1 ratio to receive either subcutaneous injections of nadroparin 3800 antiXa IU once daily or placebo, for the duration of chemotherapy or up to a maximum of 120?d. Fifteen of the 769 patients treated with nadroparin (2��0%) and 15 of the 381 patients treated with placebo (3��9%) had a thromboembolic event http://www.selleckchem.com/products/abt-199.html (either http://www.selleckchem.com/products/ABT-263.html arterial or venous) (P?=?0��024), thus, nadroparin reduced the absolute rate of thromboembolism by 50%. Five patients in the nadroparin group (0��7%) and none in the placebo group had major bleeding (P?=?0��18) (Agnelli et?al, 2009; Verso et?al, 2010). The SAVE-ONCO study, which is a large (n?=?3200) prospective, double-blind, multicentre study of the ultra-LMWH semuloparin for prophylaxis in outpatients with locally advanced or metastatic solid tumours (lung, pancreas, stomach, colorectal, bladder, or ovary), was recently published (Agnelli et?al, 2012). Patients were randomised to daily subcutaneous semuloparin 20?mg or placebo: those receiving prophylactic semuloparin had 64% relative risk reduction of VTE compared to placebo, 1��2% vs. 3��4%, (95% CI 0��21�C0��6, P? http://www.selleck.cn/products/CP-690550.html 2012). In contrast to LMWH, warfarin has been demonstrated to have no significant effect on VTE rates in a randomised placebo-controlled trial of 311 out-patients with metastatic breast cancer, treated for the duration of chemotherapy. The VTE risk reduction was 0��15 (95% CI 0��02�C1��2) with no significant increased risk of major bleeding, RR 0��52 (95% CI 0��05�C5��71) (Levine et?al, 1996). Chemotherapy is associated with a thrombotic risk over and above that due to active malignancy, whether due to therapeutic agents or central venous catheters (CVCs) used to deliver them. The available evidence does not support the use of anticoagulant prophylaxis to prevent catheter-related thrombosis in cancer patients (Kahn et?al, 2012). This issue will be further explored in detailed in a forthcoming review in this journal.